AASLD/KASL: Innovative Ideas to Change Practice

Nov 08 2025
Convention Center: Room 143, Level 1
3:45 PM - 4:45 PM

World Class Speakers

WS
Presenter

Won Sohn
Patricia Bloom, MD
Presenter

Patricia Bloom, MD

University of Michigan
YC
Presenter

Young Chang
Renumathy Dhanasekaran, MD, PhD
Presenter

Renumathy Dhanasekaran, MD, PhD

Stanford University
YL
Moderator

YOUNG-SUK LIM, MD, PhD

Asan Medical Center

Description

Continuing the successful AASLD-KASL collaboration since 2023, this session highlights practice-changing innovations in hepatology from leading researchers in the U.S. and Korea. Topics include the application of artificial intelligence for non-invasive assessment of liver fibrosis in patients with MASLD, the use of speech pattern analysis as a digital biomarker for detecting hepatic encephalopathy, clinical data on autologous bone marrow-derived mesenchymal stem cell transplantation for liver cirrhosis, and AI-powered tools that synthesize clinical guidelines to support real-time decision-making. A panel discussion will follow to explore the clinical impact, implementation challenges, and global relevance of these emerging technologies.

Journey Maps

Presentations

3:50 PM - 4:00 PM
Nov 08 2025
Washington, D.C.

AI-based Non-invasive Diagnosis of Liver Fibrosis in MASLD

Won Sohn, Presenter
Cirrhosis and Portal Hypertension
4:00 PM - 4:10 PM
Nov 08 2025
Washington, D.C.

Diagnosis of Hepatic Encephalopathy by Speech Abnormalities

Patricia Bloom, MD, Presenter
Cirrhosis and Portal Hypertension
4:10 PM - 4:20 PM
Nov 08 2025
Washington, D.C.

Stem Cell-based Regenerative Therapy for Liver Cirrhosis

Young Chang, Presenter
Cirrhosis and Portal Hypertension
4:20 PM - 4:30 PM
Nov 08 2025
Washington, D.C.

Using AI to make Practice Recommendations Based on Guidelines

Renumathy Dhanasekaran, MD, PhD, Presenter
Cirrhosis and Portal Hypertension
4:30 PM - 4:45 PM
Nov 08 2025
Washington, D.C.

Panel Discussion - All Presenters

YOUNG-SUK LIM, MD, PhD, Moderator
Cirrhosis and Portal Hypertension

Objectives

  • Evaluate the application of artificial intelligence for non-invasive assessment and staging of liver fibrosis in patients with MASLD, including advancements in imaging and algorithmic modeling.
  • Analyze speech pattern abnormalities as emerging digital biomarkers for hepatic encephalopathy and assess their diagnostic sensitivity and clinical utility.
  • Review clinical evidence on the efficacy and safety of autologous bone marrow-derived mesenchymal stem cell transplantation in the treatment of liver cirrhosis.
  • Apply AI-powered tools that synthesize hepatology clinical guidelines to support real-time, patient-specific decision-making in clinical practice.